ReviewFrontiers in immunology2019
Complement in the Pathophysiology of the Antiphospholipid Syndrome.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.Frontiers in immunology · 2026Pooled it
- Pediatric APS: State of the Art.Current rheumatology reports · 2020Pooled it
- Association of IgA antiphospholipid antibodies with hypercoagulability and inflammation in antiphospholipid syndrome.Journal of thrombosis and thrombolysis · 2026Observational
- ANA fluorescence patterns and low C4 are associated with higher antiphospholipid antibody serological intensity in routine diagnostic testing.Clinical chemistry and laboratory medicine · 2026Article
- Next-generation heparin antidotes: "Exosomes as a biocompatible alternative to protamine sulfate".Molecular biology reports · 2026Article
- Combined Obstetric and Thrombotic Complications Are Associated with Features Suggestive of an Immune-Enriched Phenotype Among Women with Thrombotic Antiphospholipid Syndrome (APS).Diagnostics (Basel, Switzerland) · 2026Article
- Systemic lupus erythematosus and pregnancy: a comprehensive clinical review of maternal, fetal, and treatment considerations.Advances in rheumatology (London, England) · 2026Review
- The evolving landscape of complement therapeutics in rheumatology.Annals of the rheumatic diseases · 2026Review
- C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges.Cells · 2026Review
- Clinical, metabolomic, and proteomic profiles associated with reproductive outcomes in unexplained recurrent pregnancy loss.Frontiers in endocrinology · 2026Article
- Animal models of antiphospholipid syndrome.Frontiers in immunology · 2026Review
- Exploratory Machine Learning Prioritizes Shared Blood Transcriptional Candidate Genes and Immune Correlates Across Antiphospholipid Syndrome and Systemic Sclerosis.BioMed research international · 2026Article
- Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study.Frontiers in immunology · 2026Article
- Article
- Role of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review).Molecular medicine reports · 2025Review
- COVID-19 vaccination around the time of conception and risk of placenta-mediated adverse pregnancy outcomes.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Activated Complement System's Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment.Journal of clinical medicine · 2025Review
- Placental Pathology in Obstetric Antiphospholipid Syndrome Beyond Thrombosis: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- Complement System Inhibitors in Nephrology: An Update-Narrative Review.International journal of molecular sciences · 2025Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Complement is a system of enzymes and regulatory proteins of the innate immune system that plays a key role in the inflammatory response to pathogenic stimuli. The complement and coagulation pathways are closely linked, and expanding data indicate that complement may be activated in patients with aPL and function as a cofactor in the pathogenesis of aPL-associated clinical events. Complement activation by aPL generates C5a, which induces neutrophil tissue factor-dependent procoagulant activity. Beta-2-glycoprotein I, the primary antigen for pathogenic aPL, has complement regulatory effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.